BioClonetics Immunotherapeutics

Progress With Each Day

Dear BioClonetics Investor and Wefunders, 
 
We wish everyone a happy holiday season and best wishes for the upcoming New Year.  We are thankful for your support and expect great progress in the coming year.

 Here are the highlights of our current developments:

As we have reported, we are continuing the development of our monoclonal antibody (called Clone 3) that has been demonstrated through testing in 5 laboratories to neutralize the HIV virus. The results of these tests demonstrating the neutralizing capability against the different strains of the virus are shown on our website at http://www.bioclonetics.com/validation.html.

We are now producing the recombinant form of the antibody – which is required by the FDA for use in patient therapy.  Once produced, we will test this recombinant form against numerous strains of the HIV virus and then confirm efficacy in tests in animal and clinical trials.

To prepare the recombinant for testing, we must identifying the molecule sequence necessary for the recombinant preparation.  We know our antibody consist of 1346 amino acids.  In my last report, we had a consensus sequence for all but 27 of these 1346.  In the most recent round of analysis, we have reduced this number to less than half of these 27.  Analysis to establish the identity of the remainder is currently underway at the facilities of Genscript (www.genscript.com) in its New Jersey and Shanghai China laboratories. The results of this analysis will be available in January.  

Once the resulting data is analyzed and we are confident of a consensus sequence, the recombinant form of our antibody will be produced and then tested against HIV isolates to confirm effectiveness.

Additionally, we are in discussions with a global non-profit organization whose sole focus in on the development of a treatment and vaccine against HIV. Our monoclonal is one of a few under consideration.  This is a promising opportunity and will be fully explored in the New Year.

We are opening a new funding round in the next few days on www.startengine.com. Funds from this fundraising round will be used in the testing of the recombinant antibody once produced.  We will keep you informed on this effort and ask that you share this information with friends once the funding campaign is opened.

We will keep you informed of our progress but rest assured that we are moving forward with each day.

Best wishes,
Charles Cotropia
CEO - BioClonetics Immunotherapeutics, Inc. 

Liked by J. W., Michael Kam, Christopher Greenstein, and 14 others